No
|
Questions
|
Answers
|
Comprehensive inquiry
|
|
1
|
How long do you have experience in treating solid tumors with PM as a surgical oncologist?
|
□ <5 years
□ 5 – 10 years
□ >10 years
|
2
|
What kind of hospital do you belong to?
|
□ University hospital
□ General hospital
□ Semi hospital
□ Cancer hospital
|
3
|
What types of solid tumors with PM do you treat mainly? (multiple selections is possible)
|
□ Ovarian cancer
□ Gastric cancer
□ Colorectal cancer
□ Pseudomyxoma peritonei
□ Hepatobiliary cancer
□ Malignant mesothelioma
□ Others: _____________________________
|
4
|
How many solid tumor patients with PM do you treat annually?
|
□ <5
□ 5 – 10
□ 10 – 30
□ 30 – 50
□ >50
|
5
|
What type of treatment do you approach for treating solid tumors with PM?
|
□ Multidisciplinary approach
□ Consultation to medical oncologists
□ Consultation to other surgical oncologists
□ Sole care
□ Transfer to other hospitals
□ Others: _____________________________
|
Procedure inquiry
|
|
6
|
If you apply PIPAC for treating solid tumors with PM, what point in the course of disease progression would you consider using PIPAC?
|
□ Primary disease, curative
□ Primary disease, palliative
□ Recurrent disease, curative
□ Recurrent disease, palliative
□ Not applicable
□ Not sure
|
7
|
When you consider PIPAC for treating primary diseases, to what extent of disease would you consider applying PIPAC?
|
□ Early-stage
□ Advanced stage
□ Both early and advanced stages
□ Not sure
|
8
|
When considering PIPAC for treating primary diseases with PM, would you consider neoadjuvant chemotherapy before PIPAC?
|
□ Yes
□ No
□ Not sure
|
9
|
What types of solid tumors with PM do you think that PIPAC can be applied to? (multiple selections is possible)
|
□ Ovarian cancer
□ Gastric cancer
□ Colorectal cancer
□ Pseudomyxoma peritonei
□ Hepatobiliary cancer
□ Malignant mesothelioma
□ Others: _____________________________
|
10
|
Do advantages such as high concentration in tissues with less drug and lower toxicities factor into the decision to use PIPAC?
|
□ Yes
□ No
□ Not sure
|
11
|
What factors do you think must be preceded PIPAC introduction?
|
□ Updates of treatment guidelines
□ Reports of results from randomized trials
□ Collaboration with specialists for IP chemotherapy
□ Reduction of complications related to IP chemotherapy
□ Others: ____________________________
|
12
|
PIPAC is expected to have fewer complications than other types of IP chemotherapy. But all treatments have complications and PIPAC is no exception. What level of complications would you consider using PIPAC?
|
□ Minor surgical complications such as postoperative pain, infection, and minor bleeding
□ Major surgical complications such as perforation and leakage at anastomotic sites
□ Hematologic toxicities
□ Non-hematologic toxicities
|
13
|
What severity of complication from PIPAC would you consider using PIPAC at? (based on the CTCAE version 5.0)
|
□ Grade 1
□ Grade 2
□ Grade 3
□ Possible regardless of complications
□ Impossible regardless of complications
|
14
|
PIPAC is known to be repeated an average of four to six cycles to maximize the treatment response.
Do you think that it is appropriate to implement PIPAC repeatedly?
|
□ Acceptable if effective
□ Willing to use it if reduced cycles
□ Possible if only one cycle
□ Not sure
|
15
|
PIPAC is performed laparoscopically under general anesthesia for 30 minutes to two hours.
Do you think general anesthesia for 30 minutes to two hours is acceptable for performing PIPAC?
|
□ Acceptable if patients are stable
□ Acceptable if local or spinal anesthesia
□ Impossible if general anesthesia is required every cycle
□ Not sure
|
16
|
According to the research results, the response rate of PIPAC is known to range from 20% to 80%.
What treatment response percentage would you expect from using PIPAC?
|
□ >80%
□ >50%
□ >20%
□ Possible regardless of response rates
|
17
|
What is the most critical factor that hinders the proper effect of PIPAC?
|
□ Performance status of patients
□ Suboptimal debulking surgery
□ Burden of repetitive surgery
□ Use of agents resistant to IV chemotherapy
□ Others: ___________________________
|
18
|
What do you think is the current level of evidence for the effects of PIPAC?
|
□ Low level, and not effective
□ Low level, but effective
□ High level, and effective
□ Not sure
|
Cost inquiry
|
|
19
|
What do you think is the reasonable cost to purchase a medical device for PIPAC?
|
□ <1,000,000 KRW
□ 1,000,000 – 5,000,000 KRW
□ 5,000,000 – 10,000,000 KRW
□ 10,000,000 – 50,000,000 KRW
□ >50,000,000 KRW
|
20
|
How much do you think is the reasonable cost to implement PIPAC once?
|
□ <1,000,000 KRW
□ 1,000,000 – 5,000,000 KRW
□ 5,000,000 – 10,000,000 KRW
□ >10,000,000 KRW
|